2016 ASCO Annual Meeting - ASCO


Powered by SmugMug Log In
Arjun Vasant Balar, MD, presenting abstract LBA4500, Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1 during Genitourinary (Nonprostate) Cancer Oral Abstract Session

Arjun Vasant Balar, MD, presenting abstract LBA4500, Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1 during Genitourinary (Nonprostate) Cancer Oral Abstract Session

Chicago, IL - 2016 ASCO Annual Meeting - Arjun Vasant Balar, MD, presenting abstract LBA4500, Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1 during Genitourinary (Nonprostate) Cancer Oral Abstract Session at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Sunday, June 5, 2016. Over 30,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 52nd Annual Meeting which is being held at the McCormick Place convention center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Brian Powers 2016 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org